BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011;33:185-193. [PMID: 21083671 DOI: 10.1111/j.1365-2036.2010.04509.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 90] [Article Influence: 9.1] [Reference Citation Analysis]
Number Citing Articles
1 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
2 Reinisch W, Travis S, Hanauer S, Wang H, Shara N, Harris MS. AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study. Inflamm Bowel Dis 2014;20:872-81. [PMID: 24694794 DOI: 10.1097/MIB.0000000000000031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
3 Lewis RT, Bleier JI. Surgical treatment of anorectal crohn disease. Clin Colon Rectal Surg. 2013;26:90-99. [PMID: 24436656 DOI: 10.1055/s-0033-1348047] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
4 Scharl M, Rogler G, Biedermann L. Fistulizing Crohn's Disease. Clin Transl Gastroenterol. 2017;8:e106. [PMID: 28703786 DOI: 10.1038/ctg.2017.33] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
5 Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Review of Clinical Immunology 2014;9:77-92. [DOI: 10.1586/eci.12.91] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
6 Pedersen KE, Lightner AL. Managing Complex Perianal Fistulizing Disease. J Laparoendosc Adv Surg Tech A 2021;31:890-7. [PMID: 34314631 DOI: 10.1089/lap.2021.0285] [Reference Citation Analysis]
7 Spinelli A, Armuzzi A, Ciccocioppo R, Danese S, Gionchetti P, Luglio G, Orlando A, Rispo A, Rizzello F, Sofo L, Solina G, Poggioli G. Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. Digestive and Liver Disease 2020;52:506-15. [DOI: 10.1016/j.dld.2019.11.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wise PE, Schwartz DA. The evaluation and treatment of Crohn perianal fistulae: EUA, EUS, MRI, and other imaging modalities. Gastroenterol Clin North Am. 2012;41:379-391. [PMID: 22500524 DOI: 10.1016/j.gtc.2012.01.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
9 Marzo M, Felice C, Pugliese D, Andrisani G, Mocci G, Armuzzi A, Guidi L. Management of perianal fistulas in Crohn’s disease: An up-to-date review. World J Gastroenterol 2015; 21(5): 1394-1403 [PMID: 25663759 DOI: 10.3748/wjg.v21.i5.1394] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
10 Wiese DM, Beaulieu D, Slaughter JC, Horst S, Wagnon J, Duley C, Annis K, Nohl A, Herline A, Muldoon R, Geiger T, Wise PE, Schwartz DA. Use of Endoscopic Ultrasound to Guide Adalimumab Treatment in Perianal Crohn's Disease Results in Faster Fistula Healing. Inflamm Bowel Dis 2015;21:1594-9. [PMID: 25985245 DOI: 10.1097/MIB.0000000000000409] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
11 Song YD, Liu SX, Zhong YQ. Biological agents for treatment of inflammatory bowel disease: Research progress and associated risks. Shijie Huaren Xiaohua Zazhi 2016; 24(19): 2964-2973 [DOI: 10.11569/wcjd.v24.i19.2964] [Reference Citation Analysis]
12 Kotze PG, Shen B, Lightner A, Yamamoto T, Spinelli A, Ghosh S, Panaccione R. Modern management of perianal fistulas in Crohn's disease: future directions. Gut 2018;67:1181-94. [PMID: 29331943 DOI: 10.1136/gutjnl-2017-314918] [Cited by in Crossref: 77] [Cited by in F6Publishing: 59] [Article Influence: 19.3] [Reference Citation Analysis]
13 Modha K, Navaneethan U. Advanced therapeutic endoscopist and inflammatory bowel disease: Dawn of a new role. World J Gastroenterol 2014; 20(13): 3485-3494 [PMID: 24707131 DOI: 10.3748/wjg.v20.i13.3485] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rackovsky O, Hirten R, Ungaro R, Colombel JF. Clinical updates on perianal fistulas in Crohn's disease. Expert Rev Gastroenterol Hepatol. 2018;12:597-605. [PMID: 29792734 DOI: 10.1080/17474124.2018.1480936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Molendijk I, Nuij VJ, van der Meulen-de Jong AE, van der Woude CJ. Disappointing durable remission rates in complex Crohn's disease fistula. Inflamm Bowel Dis. 2014;20:2022-2028. [PMID: 25159455 DOI: 10.1097/mib.0000000000000148] [Cited by in Crossref: 85] [Cited by in F6Publishing: 37] [Article Influence: 12.1] [Reference Citation Analysis]
16 Sordo-Mejia R, Gaertner WB. Multidisciplinary and evidence-based management of fistulizing perianal Crohn’s disease. World J Gastrointest Pathophysiol 2014; 5(3): 239-251 [PMID: 25133026 DOI: 10.4291/wjgp.v5.i3.239] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
17 Schwartz DA, Wang A, Ozbay B, Skup M, Eichner SF, Lin J, Chao J. Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn's Disease Treated with Biologics with or Without Previous Seton Placement. Inflamm Bowel Dis 2017;23:1860-6. [PMID: 28858069 DOI: 10.1097/MIB.0000000000001243] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
18 Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, Rodriguez-de-Santiago E, Lopez-Sanroman A. Management of complex perianal Crohn's disease. Ann Gastroenterol. 2017;30:33-44. [PMID: 28042236 DOI: 10.20524/aog.2016.0099] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
19 Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol 2011;4:375-89. [PMID: 22043230 DOI: 10.1177/1756283X11413315] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
20 Juncadella AC, Alame AM, Sands LR, Deshpande AR. Perianal Crohn’s disease: A review. Postgraduate Medicine 2015;127:266-72. [DOI: 10.1080/00325481.2015.1023160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
21 Blonski W, Buchner AM, Lichtenstein GR. Patient adherence and efficacy of certolizumab pegol in the management of Crohn's disease. Clin Med Insights Gastroenterol 2012;5:11-21. [PMID: 24833930 DOI: 10.4137/CGast.S7613] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
22 Abraham BP, Ahmed T, Ali T. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. In: Greenwood-van Meerveld B, editor. Gastrointestinal Pharmacology. Cham: Springer International Publishing; 2017. pp. 115-46. [DOI: 10.1007/164_2016_122] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
23 Wu AA, Barros JR, Ramdeen M, Baima JP, Saad-Hossne R, Sassaki LY. FACTORS ASSOCIATED WITH PATIENT´S PREFERENCE IN CHOOSING THEIR THERAPY FOR INFLAMMATORY BOWEL DISEASE IN BRAZIL. Arq Gastroenterol 2020;57:491-7. [PMID: 33331482 DOI: 10.1590/S0004-2803.202000000-86] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Steinhart AH, Panaccione R, Targownik L, Bressler B, Khanna R, Marshall JK, Afif W, Bernstein CN, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus. Inflammatory Bowel Diseases 2019;25:1-13. [DOI: 10.1093/ibd/izy247] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 9.5] [Reference Citation Analysis]
25 Wiese DM, Schwartz DA. Managing Perianal Crohn’s Disease. Curr Gastroenterol Rep 2012;14:153-61. [DOI: 10.1007/s11894-012-0243-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
26 Lightner AL. Challenges in Crohn's disease: Complex perianal Crohn's disease. Seminars in Colon and Rectal Surgery 2020;31:100747. [DOI: 10.1016/j.scrs.2020.100747] [Reference Citation Analysis]
27 Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014;11:243-55. [PMID: 24393836 DOI: 10.1038/nrgastro.2013.253] [Cited by in Crossref: 128] [Cited by in F6Publishing: 115] [Article Influence: 16.0] [Reference Citation Analysis]
28 Evans AT, Lee SD. A review and expert opinion of the use of certolizumab for Crohn's disease. Expert Opin Biol Ther 2012;12:363-70. [PMID: 22339409 DOI: 10.1517/14712598.2012.658770] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
29 Deeks ED. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases. BioDrugs 2016;30:607-17. [PMID: 27704400 DOI: 10.1007/s40259-016-0197-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
30 Lee MJ, Parker CE, Taylor SR, Guizzetti L, Feagan BG, Lobo AJ, Jairath V. Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1879-1892. [PMID: 29374617 DOI: 10.1016/j.cgh.2018.01.030] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 16.5] [Reference Citation Analysis]
31 Kane SV, Neis B, Becker BD, Bruining D, Faubion WA, Kisiel J, Loftus EV Jr, Pardi D, Raffals L, Schroeder K, Tremaine WJ. Letter: Effectiveness of split-dose certolizumab pegol for Crohn's disease. Aliment Pharmacol Ther 2013;38:1412. [PMID: 24206378 DOI: 10.1111/apt.12506] [Reference Citation Analysis]
32 Sahnan K, Adegbola SO, Fareleira A, Hart A, Warusavitarne J. Medical-surgical Combined Approach in Perianal Fistulizing Crohn's Disease (CD): Doing it Together. Curr Drug Targets 2019;20:1373-83. [PMID: 31109272 DOI: 10.2174/1389450120666190520103454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Panés J, Rimola J. Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol 2017;14:652-64. [PMID: 28790453 DOI: 10.1038/nrgastro.2017.104] [Cited by in Crossref: 113] [Cited by in F6Publishing: 92] [Article Influence: 22.6] [Reference Citation Analysis]
34 Mahmoud NN, Halwani Y, Montbrun SD, Shah PM, Hedrick TL, Rashid F, Schwartz DA, Dalal RL, Kamiński JP, Zaghiyan K, Fleshner PR, Weissler JM, Fischer JP. Current management of perianal Crohn’s disease. Current Problems in Surgery 2017;54:262-98. [DOI: 10.1067/j.cpsurg.2017.02.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
35 Gecse KB, Sebastian S, Hertogh Gd, Yassin NA, Kotze PG, Reinisch W, Spinelli A, Koutroubakis IE, Katsanos KH, Hart A, van den Brink GR, Rogler G, Bemelman WA. Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs. J Crohns Colitis. 2016;10:758-765. [PMID: 26826183 DOI: 10.1093/ecco-jcc/jjw039] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
36 Klag T, Goetz M, Stange EF, Wehkamp J. Medical Therapy of Perianal Crohn’s Disease. Viszeralmedizin. 2015;31:265-272. [PMID: 26557835 DOI: 10.1159/000434664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
37 Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature. Scand J Gastroenterol. 2021;56:53-58. [PMID: 33264569 DOI: 10.1080/00365521.2020.1854848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:2733-47. [DOI: 10.1097/mib.0000000000000923] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
39 Rubín de Célix Vargas C, Algaba A, Guerra I, Serrano Á, Pérez-Viejo E, Aulló C, Bermejo F. Resources used in the treatment of perianal Crohn's disease and the results in a real-life cohort. Gastroenterol Hepatol 2018;41:353-61. [PMID: 29759924 DOI: 10.1016/j.gastrohep.2018.04.006] [Reference Citation Analysis]
40 Oliveira SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. BMJ. 2017;357:j2083. [PMID: 28566467 DOI: 10.1136/bmj.j2083] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
41 Gouldthorpe O, Catto-Smith AG, Alex G. Biologics in paediatric Crohn's disease. Gastroenterol Res Pract 2011;2011:287574. [PMID: 22144993 DOI: 10.1155/2011/287574] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
42 Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol 2014; 20(12): 3146-3152 [PMID: 24696600 DOI: 10.3748/wjg.v20.i12.3146] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]
43 Steinhart AH, Panaccione R, Targownik L, Bressler B, Khanna R, Marshall JK, Afif W, Bernstein CN, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. J Can Assoc Gastroenterol. 2018;1:141-154. [PMID: 31799497 DOI: 10.1093/jcag/gwy047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
44 Affronti A, Orlando A, Cottone M. An update on medical management on Crohn’s disease. Expert Opin Pharmacother. 2015;16:63-78. [PMID: 25418125 DOI: 10.1517/14656566.2015.981525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
45 Lightner AL, Ashburn JH, Brar MS, Carvello M, Chandrasinghe P, van Overstraeten ADB, Fleshner PR, Gallo G, Kotze PG, Holubar SD, Reza LM, Spinelli A, Strong SA, Tozer PJ, Truong A, Warusavitarne J, Yamamoto T, Zaghiyan K. Fistulizing Crohn's disease. Current Problems in Surgery 2020;57:100808. [DOI: 10.1016/j.cpsurg.2020.100808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
46 Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, Panés J, van Assche G, Liu Z, Hart A, Levesque BG, D'Haens G; World Gastroenterology Organization, International Organisation for Inflammatory Bowel Diseases IOIBD, European Society of Coloproctology and Robarts Clinical Trials., World Gastroenterology Organization International Organisation for Inflammatory Bowel Diseases IOIBD European Society of Coloproctology and Robarts Clinical Trials. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut 2014;63:1381-92. [PMID: 24951257 DOI: 10.1136/gutjnl-2013-306709] [Cited by in Crossref: 243] [Cited by in F6Publishing: 193] [Article Influence: 30.4] [Reference Citation Analysis]
47 Boscá MM, Alós R, Maroto N, Gisbert JP, Beltrán B, Chaparro M, Nos P, Mínguez M, Hinojosa J. Recommendations of the Crohn’s Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn’s disease. Gastroenterología y Hepatología (English Edition) 2020;43:155-68. [DOI: 10.1016/j.gastre.2019.09.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Vogel JD, Johnson EK, Morris AM, Paquette IM, Saclarides TJ, Feingold DL, Steele SR. Clinical Practice Guideline for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula. Diseases of the Colon & Rectum 2016;59:1117-33. [DOI: 10.1097/dcr.0000000000000733] [Cited by in Crossref: 118] [Cited by in F6Publishing: 36] [Article Influence: 19.7] [Reference Citation Analysis]
49 Zaboli P, Abdollahi M, Mozaffari S, Nikfar S. Tumor Necrosis Factor-alpha Antibodies in Fistulizing Crohn's Disease: An Updated Systematic Review and Meta-analysis. J Res Pharm Pract 2017;6:135-44. [PMID: 29026838 DOI: 10.4103/jrpp.JRPP_17_46] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Bermejo F, Guerra I, Algaba A, López-Sanromán A. Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease. Drugs 2018;78:1-18. [PMID: 29139091 DOI: 10.1007/s40265-017-0842-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
51 Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185-210. [PMID: 21552489 DOI: 10.2147/dddt.s11290] [Cited by in Crossref: 137] [Cited by in F6Publishing: 76] [Article Influence: 12.5] [Reference Citation Analysis]
52 Ghazi LJ, Schwartz DA. Perianal Crohn's Disease—A Gastroenterologist's Perspective. Seminars in Colon and Rectal Surgery 2012;23:117-24. [DOI: 10.1053/j.scrs.2012.04.005] [Reference Citation Analysis]
53 Nikfar S, Ehteshami-Afshar S, Abdollahi M. Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn's Disease? A Meta-analysis of Controlled Clinical Trials. Iran Red Crescent Med J 2013;15:668-75. [PMID: 24578833 DOI: 10.5812/ircmj.11258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
54 Abushamma S, Ballard DH, Smith RK, Deepak P. Multidisciplinary management of perianal Crohn's disease. Curr Opin Gastroenterol 2021;37:295-305. [PMID: 33899777 DOI: 10.1097/MOG.0000000000000751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther. 2014;14:583-600. [PMID: 24502344 DOI: 10.1517/14712598.2014.885945] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
56 Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160:2512-2556.e9. [PMID: 34051985 DOI: 10.1053/j.gastro.2021.04.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
57 Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01042-9. [PMID: 34597729 DOI: 10.1016/j.cgh.2021.09.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
58 Dalal RL, Schwartz DA. The Gastroenterologist's Role in Management of Perianal Fistula. Gastrointest Endosc Clin N Am 2016;26:693-705. [PMID: 27633597 DOI: 10.1016/j.giec.2016.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Boscá MM, Alós R, Maroto N, Gisbert JP, Beltrán B, Chaparro M, Nos P, Mínguez M, Hinojosa J. Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease. Gastroenterol Hepatol 2020;43:155-68. [PMID: 31870681 DOI: 10.1016/j.gastrohep.2019.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Adegbola SO, Sahnan K, Twum-Barima C, Iqbal N, Reza L, Lung P, Warusavitarne J, Tozer P, Hart A. Current review of the management of fistulising perianal Crohn's disease. Frontline Gastroenterol 2021;12:515-23. [PMID: 34712470 DOI: 10.1136/flgastro-2020-101489] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
61 Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy. World J Gastroenterol 2017; 23(34): 6197-6200 [PMID: 28974885 DOI: 10.3748/wjg.v23.i34.6197] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
62 Bislenghi G, Wolthuis A, Van Assche G, Vermeire S, Ferrante M, D'Hoore A. Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease. Expert Opin Biol Ther. 2019;19:607-616. [PMID: 31121104 DOI: 10.1080/14712598.2019.1623876] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
63 Miranda EF, Nones RB, Kotze PG. Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn's disease: a narrative review. Intest Res 2021;19:255-64. [PMID: 33147899 DOI: 10.5217/ir.2020.00029] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Geldof J, Iqbal N, Warusavitarne J, Hart A. The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CD. Clin Colon Rectal Surg 2022;35:021-31. [DOI: 10.1055/s-0041-1740035] [Reference Citation Analysis]
65 Sugrue J, Nordenstam J, Abcarian H, Bartholomew A, Schwartz JL, Mellgren A, Tozer PJ. Pathogenesis and persistence of cryptoglandular anal fistula: a systematic review. Tech Coloproctol 2017;21:425-32. [PMID: 28620877 DOI: 10.1007/s10151-017-1645-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
66 Odes S, Greenberg D. A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoecon Outcomes Res 2014;6:431-43. [PMID: 25336980 DOI: 10.2147/CEOR.S39212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
67 Adegbola SO, Pisani A, Sahnan K, Tozer P, Ellul P, Warusavitarne J. Medical and surgical management of perianal Crohn's disease. Ann Gastroenterol 2018;31:129-39. [PMID: 29507460 DOI: 10.20524/aog.2018.0236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
68 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
69 Lopez N, Ramamoorthy S, Sandborn WJ. Recent advances in the management of perianal fistulizing Crohn's disease: lessons for the clinic. Expert Rev Gastroenterol Hepatol. 2019;13:563-577. [PMID: 31023087 DOI: 10.1080/17474124.2019.1608818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
70 Hirten RP, Shah S, Sachar DB, Colombel JF. The Management of Intestinal Penetrating Crohn's Disease. Inflamm Bowel Dis 2018;24:752-65. [PMID: 29528400 DOI: 10.1093/ibd/izx108] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
71 Lightner AL, Faubion WA, Fletcher JG. Interdisciplinary Management of Perianal Crohn's Disease. Gastroenterology Clinics of North America 2017;46:547-62. [DOI: 10.1016/j.gtc.2017.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
72 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
73 Molendijk I, Peeters KC, Baeten CI, Veenendaal RA, van der Meulen-de Jong AE. Improving the outcome of fistulising Crohn's disease. Best Practice & Research Clinical Gastroenterology 2014;28:505-18. [DOI: 10.1016/j.bpg.2014.04.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
74 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517. [PMID: 29610508 DOI: 10.1038/ajg.2018.27] [Cited by in Crossref: 390] [Cited by in F6Publishing: 311] [Article Influence: 97.5] [Reference Citation Analysis]
75 Morrow T, Felcone LH. Defining the difference: What Makes Biologics Unique. Biotechnol Healthc. 2004;1:24-29. [PMID: 23393437 DOI: 10.1177/2050640615590302] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 8.6] [Reference Citation Analysis]
76 Zulqarnain M, Deepak P, Yarur AJ. Therapeutic Drug Monitoring in Perianal Fistulizing Crohn’s Disease. JCM 2022;11:1813. [DOI: 10.3390/jcm11071813] [Reference Citation Analysis]
77 Garcia-Olmo D, Schwartz DA. Cumulative Evidence That Mesenchymal Stem Cells Promote Healing of Perianal Fistulas of Patients With Crohn’s Disease--Going From Bench to Bedside. Gastroenterology. 2015;149:853-857. [PMID: 26311275 DOI: 10.1053/j.gastro.2015.08.038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
78 Wang X, Zhou F, Zhao J, Zhou R, Huang M, Li J, Wang W, Xu S, Xia B. Elevated risk of opportunistic viral infection in patients with Crohn’s disease during biological therapies: a meta analysis of randomized controlled trials. Eur J Clin Pharmacol 2013;69:1891-9. [DOI: 10.1007/s00228-013-1559-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
79 Scott FI, Osterman MT. Medical management of crohn disease. Clin Colon Rectal Surg 2013;26:67-74. [PMID: 24436652 DOI: 10.1055/s-0033-1348043] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
80 Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFα therapy to treat Crohn's disease. Expert Opin Drug Saf 2015;14:31-44. [PMID: 25400161 DOI: 10.1517/14740338.2015.976610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
81 Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn's Disease. Int J Mol Sci 2018;19:E2244. [PMID: 30065229 DOI: 10.3390/ijms19082244] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 20.0] [Reference Citation Analysis]
82 Tozer P, Borowski DW, Gupta A, Yassin N, Phillips R, Hart A. Managing perianal Crohn's fistula in the anti-TNFα era. Tech Coloproctol 2015;19:673-8. [PMID: 26264168 DOI: 10.1007/s10151-015-1332-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
83 Feroz SH, Ahmed A, Muralidharan A, Thirunavukarasu P. Comparison of the Efficacy of the Various Treatment Modalities in the Management of Perianal Crohn's Fistula: A Review. Cureus 2020;12:e11882. [PMID: 33415035 DOI: 10.7759/cureus.11882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Meng ZW, Baumgart DC. Darvadstrocel for the treatment of perianal fistulas in Crohn's disease. Expert Rev Gastroenterol Hepatol 2020;14:405-10. [PMID: 32354239 DOI: 10.1080/17474124.2020.1764349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Williams JL, Shaffer VO. Modern Management of Perianal Crohn's Disease: A Review. Am Surg 2020;:3134820956331. [PMID: 33345571 DOI: 10.1177/0003134820956331] [Reference Citation Analysis]
86 Kulkarni S, Gomara R, Reeves-garcia J, Hernandez E, Restrepo R. MRI-Based Score Helps in Assessing the Severity and in Follow-up of Pediatric Patients With Perianal Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2014;58:252-7. [DOI: 10.1097/mpg.0000000000000199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
87 Kawalec P, Mikrut A, Wiśniewska N, Pilc A. Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci 2013;9:765-79. [PMID: 24273556 DOI: 10.5114/aoms.2013.38670] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
88 Deepak P, Ludwig DR, Fidler JL, Guglielmo FF, Bruining DH. Medical and Endoscopic Management of Crohn Disease. Top Magn Reson Imaging 2021;30:43-61. [PMID: 33528211 DOI: 10.1097/RMR.0000000000000267] [Reference Citation Analysis]
89 Al-Maawali AK, Nguyen P, Phang PT. Modern Treatments and Stem Cell Therapies for Perianal Crohn's Fistulas. Can J Gastroenterol Hepatol 2016;2016:1651570. [PMID: 28053967 DOI: 10.1155/2016/1651570] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
90 El-Hag K, Renzulli P, Franzen D, Kohler M. Colobronchial fistula: a rare cause of non-resolving pneumonia in Crohn's disease. BMJ Case Rep 2018;2018:bcr-2018-224408. [PMID: 30131411 DOI: 10.1136/bcr-2018-224408] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
91 de Zoeten EF, Pasternak BA, Mattei P, Kramer RE, Kader HA. Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement. J Pediatr Gastroenterol Nutr. 2013;57:401-412. [PMID: 23974063 DOI: 10.1097/mpg.0b013e3182a025ee] [Cited by in Crossref: 63] [Cited by in F6Publishing: 17] [Article Influence: 7.9] [Reference Citation Analysis]